{"title":"Nonsteroidal Approaches for Atopic Dermatitis®: A Clinical Update.","authors":"Peter Y Ch'en, Peter A Lio","doi":"10.1089/derm.2023.0373","DOIUrl":null,"url":null,"abstract":"<p><p><u><b><i></i></b></u> Topical corticosteroids (TCSs) are the most widely used treatment for atopic Dermatitis® (AD), but they can have adverse effects such as skin atrophy, telangiectasias, and hypopigmentation, especially with prolonged use of higher potency steroids. Many patients also have a fear of using TCSs, known as \"corticophobia.\" With the development of biologics and Janus kinase inhibitors, a nonsteroidal approach to the treatment of AD may be possible and may be preferred by certain patients. Given what is known about these nonsteroidal therapies, we propose a structured treatment ladder and action plan that can guide clinicians and patients on the use of these therapies for the treatment of AD. The ladder divides nonsteroidal medication classes into treatments for exacerbation versus maintenance therapies in an escalating order of increasing potential for adverse effects, both real and perceived. This treatment algorithm proposal paves the way for a potential nonsteroidal approach to managing AD.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"596-604"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatitis : contact, atopic, occupational, drug","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/derm.2023.0373","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/6 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Topical corticosteroids (TCSs) are the most widely used treatment for atopic Dermatitis® (AD), but they can have adverse effects such as skin atrophy, telangiectasias, and hypopigmentation, especially with prolonged use of higher potency steroids. Many patients also have a fear of using TCSs, known as "corticophobia." With the development of biologics and Janus kinase inhibitors, a nonsteroidal approach to the treatment of AD may be possible and may be preferred by certain patients. Given what is known about these nonsteroidal therapies, we propose a structured treatment ladder and action plan that can guide clinicians and patients on the use of these therapies for the treatment of AD. The ladder divides nonsteroidal medication classes into treatments for exacerbation versus maintenance therapies in an escalating order of increasing potential for adverse effects, both real and perceived. This treatment algorithm proposal paves the way for a potential nonsteroidal approach to managing AD.
外用皮质类固醇(TCS)是特应性皮炎(AD)最广泛使用的治疗方法,但它可能会产生皮肤萎缩、毛细血管扩张和色素沉着等不良反应,尤其是长期使用高浓度类固醇时。许多患者还害怕使用 TCS,即所谓的 "皮质恐惧症"。随着生物制剂和 Janus 激酶抑制剂的发展,非甾体类药物治疗 AD 也许是可行的,而且可能是某些患者的首选。鉴于对这些非类固醇疗法的了解,我们提出了一个结构化的治疗阶梯和行动计划,以指导临床医生和患者使用这些疗法治疗 AD。该阶梯将非甾体类药物分为病情加重治疗和维持治疗两类,并按照不良反应(包括真实的和感知到的)可能性增加的顺序依次递增。这一治疗算法建议为非甾体类药物治疗 AD 的潜在方法铺平了道路。